Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
chrs · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Coherus Oncology, Inc. (CHRS) measures how much investors pay for each dollar of the company's trailing earnings. CHRS's current PE ratio of N/A is calculated by dividing its stock price of $1.42 by its TTM earnings per share of -$1.11.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%9.4x
MedianQ3 · 75%14.0x
Max
At N/A, CHRS's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Coherus Oncology, Inc.You CHRS | $174M | N/A | — | -$1.11 |
 Avalo Therapeutics, Inc. AVTX | $144M | N/A | — | -$5.84 |
 C4 Therapeutics, Inc. CCCC | $297M | N/A | — | -$1.27 |
 Codexis, Inc. CDXS | $237M | N/A | — | -$0.50 |
 Insight Molecular Diagnostics Inc. IMDX | $154M | N/A | — | -$1.65 |
 Invivyd, Inc. IVVD | $135M | N/A | — | -$0.30 |
 OmniAb, Inc. OABI | $272M | N/A | — | -$0.57 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.41 | — | |
2024-12-31 FY2024 | 5.55x | $0.25 | — | |
2023-12-31 FY2023 | — | $-2.53 | — | |
2022-12-31 FY2022 | — | $-3.76 | — | |
2021-12-31 FY2021 | — | $-3.81 | — | |
2020-12-31 FY2020 | 9.39x | $1.85 | -32.8% | |
2019-12-31 FY2019 | 13.97x | $1.29 | — | |
2018-12-31 FY2018 | — | $-3.22 | — | |
2017-12-31 FY2017 | — | $-4.48 | — | |
2016-12-31 FY2016 | — | $-3.04 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Coherus Oncology, Inc. (CHRS) measures how much investors pay for each dollar of the company's trailing earnings. CHRS's current PE ratio of N/A is calculated by dividing its stock price of $1.42 by its TTM earnings per share of -$1.11.
Frequently asked questions
CHRS pe ratio · 6 questionsCHRS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.42 and TTM EPS of -$1.11. Data sourced from Financial Modeling Prep via CHRS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Coherus Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08